Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus paclitaxel versus placebo plus paclitaxel in PIK3CA/AKT1/PTEN-altered advanced breast cancer
2017-001548-36Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer, triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative breast cancer comparing Ipatasertib + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Jul 2017; status: completed.
02
Drugs
ipatasertib
03
Conditions
breast cancertriple-negative breast cancer (TNBC)hormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on 2017-001548-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001548-36.